South Korean biopharmaceutical company GC Pharma (KRX: 006280) stated on Friday its K-IFRS net income of KRW56.7bn for the year ended 31 December 2017.

This marks a growth of 13% in K-IFRS net income when compared to the prior year of 2016.

Revenues of KRW1.29tn were generated in 2017, a rise over revenues of KRW1.20tn in 2016, which was driven mainly by plasma products and vaccines sales.

Operating income of KRW90.3bn were recorded in 2017, up 15.1% from operating income of KRW78.5bn in 2016, primarily due to higher revenue from plasma and vaccine products and 1.3% lower SG&A expense rate.

(USD1=KRW1,08)